Loading...
ALPN logo

Alpine Immune Sciences, Inc.NasdaqGM:ALPN Stock Report

Market Cap US$4.5b
Share Price
n/a
US$62
n/aintrinsic discount
1Y518.2%
7D0.03%
1D
Portfolio Value
​
View

Alpine Immune Sciences, Inc.

NasdaqGM:ALPN Stock Report

Market Cap: US$4.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alpine Immune Sciences (ALPN) Stock Overview

Operates as a clinical-stage biopharmaceutical company. More details

ALPN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 34.24% per year

Risk Analysis

Earnings are forecast to decline by an average of 9.9% per year for the next 3 years

Volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year


ALPN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Alpine Immune Sciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alpine Immune Sciences
Historical stock prices
Current Share PriceUS$64.97
52 Week HighUS$65.00
52 Week LowUS$8.33
Beta0.97
1 Month Change0.65%
3 Month Change113.79%
1 Year Change518.17%
3 Year Change520.53%
5 Year Change1,270.68%
Change since IPO580.31%

Recent News & Updates

Recent updates

Seeking Alpha • Apr 11

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Summary Vertex Pharmaceuticals Incorporated is acquiring Alpine Immune Sciences, Inc. for $4.9 billion in cash to obtain the use of povetacicept for IgAN and other kidney disorders. Positive results of povetacicept for treatment of patients with IgAN were first revealed at ASN Kidney Week In November 2023, with additional positive data just released the other day. Povetacicept is also being explored in RUBY-4 study targeting patients with autoimmune cytopenias; Data from this study will be released at a medical meeting in the 1st half of 2024. A phase 2 trial initiation, using povetacicept for the treatment of patients with systemic lupus erythematosus, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha
Analysis Article • Mar 21

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) investors will be delighted, with the company turning in some strong...
Analysis Article • Mar 20

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Alpine...
Seeking Alpha • Mar 07

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Summary Alpine Immune Sciences has discarded two drug candidates since joining the Nasdaq in 2027, but its stock price has risen >200% in six months owing to its latest lead candidate. Povetacicept has shown promising results in a Phase 2 study for the treatment of IgA nephropathy, with significant reductions in proteinuria and disease-related biomarkers. The market potential for povetacicept in the IgA nephropathy indication alone is estimated to be worth billions of dollars, making it a potentially lucrative asset for Alpine. There's plenty of competition in the IgAN space, however, including two recently approved drugs and two pipeline assets with the same MoA as povetacicept. These assets belong to Vera Therapeutics and Novartis, and it's difficult to pick a winning candidate, albeit Alpine's is the least advanced. As such, I'm not sure the company fully justifies its $2.5bn market cap - I'm on the sidelines until more data is shared. Read the full article on Seeking Alpha
Analysis Article • Feb 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...
Analysis Article • Dec 19

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...
Analysis Article • Sep 23

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 11

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

With a median price-to-sales (or "P/S") ratio of close to 11.6x in the Biotechs industry in the United States, you...
Analysis Article • Dec 12

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Sep 20

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Alpine Immune Sciences (NASDAQ:ALPN) stock dropped 13% after the bell on Tuesday after the firm announced an underwritten public offering of $100M of shares and pre-funded warrants to buy stock. Underwriters will be granted an option for 30 days to buy up to an additional $15M of shares at the offering price. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms.
Analysis Article • Aug 09

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Apr 25

Alpine: Rest Before Rallying Again

Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure three interesting partnerships. Despite not having much further catalyst this year, the company is set to release data of a Phase 1 trial studying ALPN303 by mid-year.
Analysis Article • Apr 12

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Sep 18

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Aug 18

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Celebrations may be in order for Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shareholders, with the analysts...

Shareholder Returns

ALPNUS BiotechsUS Market
7D0.03%1.2%1.6%
1Y518.2%35.1%28.2%

Return vs Industry: ALPN exceeded the US Biotechs industry which returned 5.8% over the past year.

Return vs Market: ALPN exceeded the US Market which returned 26% over the past year.

Price Volatility

Is ALPN's price volatile compared to industry and market?
ALPN volatility
ALPN Average Weekly Movement13.8%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: ALPN's share price has been volatile over the past 3 months.

Volatility Over Time: ALPN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2007142Mitch Goldwww.alpineimmunesciences.com

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company’s product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.

Alpine Immune Sciences, Inc. Fundamentals Summary

How do Alpine Immune Sciences's earnings and revenue compare to its market cap?
ALPN fundamental statistics
Market capUS$4.46b
Earnings (TTM)-US$36.84m
Revenue (TTM)US$56.52m
78.9x
P/S Ratio
-121.0x
P/E Ratio

Is ALPN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALPN income statement (TTM)
RevenueUS$56.52m
Cost of RevenueUS$83.78m
Gross Profit-US$27.26m
Other ExpensesUS$9.58m
Earnings-US$36.84m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.54
Gross Margin-48.23%
Net Profit Margin-65.17%
Debt/Equity Ratio0%

How did ALPN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/21 07:35
End of Day Share Price 2024/05/17 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alpine Immune Sciences, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gao Yi ChenBerenberg
Vamil DivanGuggenheim Securities, LLC
Joseph PantginisH.C. Wainwright & Co.